Pharmaceutical Raw Material CAS 15307-79-6 Diclofenac Sodium Powder
Diclofenac sodium has a effect on anti-inflammatory, analgesic and antipyretic.Diclofenac Sodium is the salt form of diclofenac, an active metabolite of the NSAID aceclofenac (sc-217557). Hydrolysis of aceclofenac, an inhibitor of interleukin-1B-induced prostaglandin E2 production with no inhibitory activity against Cox (cyclooxygenase), generates diclofenac, an inhibitor of both Cox-1 and Cox-2. Oxidation of diclofenac produces the metabolite 4'-hydroxy diclofenac (sc-202423) which demonstrates specific inhibition of Cox-2. Inhibition of Cox by diclofenac and 4'-hydroxy diclofenac suppresses prostaglandin E2 synthesis, producing antiinflammatory and analgesic effects. Diclofenac is also shown to stabilize the native tetrameric conformation of transthyretin (TTR) fibrils, preventing the formation of insolubleamyloidogenic TTR deposits. Diclofenac Sodium is a substrate of CYP2C9.
| Product name | Diclofenac sodium |
| Cas No. | 15307-79-6 |
| Molecular Formula | C14H10Cl2NNaO2 |
| Appearance | White crystalline powder |
Diclofenac sodium has a effect on anti-inflammatory, analgesic and antipyretic.Diclofenac Sodium is the salt form of diclofenac, an active metabolite of the NSAID aceclofenac (sc-217557). Hydrolysis of aceclofenac, an inhibitor of interleukin-1B-induced prostaglandin E2 production with no inhibitory activity against Cox (cyclooxygenase), generates diclofenac, an inhibitor of both Cox-1 and Cox-2. Oxidation of diclofenac produces the metabolite 4'-hydroxy diclofenac (sc-202423) which demonstrates specific inhibition of Cox-2. Inhibition of Cox by diclofenac and 4'-hydroxy diclofenac suppresses prostaglandin E2 synthesis, producing antiinflammatory and analgesic effects. Diclofenac is also shown to stabilize the native tetrameric conformation of transthyretin (TTR) fibrils, preventing the formation of insolubleamyloidogenic TTR deposits. Diclofenac Sodium is a substrate of CYP2C9.